logo-loader
viewAstraZeneca

AstraZeneca stops chronic kidney disease treatment trial early after “overwhelming efficacy”

The pharma company also announced Imfinzi has been approved for small cell lung cancer in combination with chemotherapies

AstraZeneca - AstraZeneca stops trial early for “overwhelming efficacy”

AstraZeneca PLC (LON:AZN) has stopped a late-stage trial of its chronic kidney disease treatment as it showed “overwhelming efficacy”.

An independent committee advised the FTSE 100-listed company to halt the studies for Farxiga, which is already under review to treat patients with heart failure.

READ: AstraZeneca posts negative results for late-stage bladder cancer treatment

AstraZeneca will now initiate discussions with global health authorities regarding early regulatory submissions.

In a note to clients, analysts at Shore Capital said they expect Farxiga to generate US$3bn by 2024.

In a separate announcement, the pharma giant also said that its Imfinzi drug has been approved in the US as a first-line treatment for extensive-stage small cell lung cancer, in combination with chemotherapies.

Imfinzi, which has already been approved for other types of cancer, is expected to generate sales of US$2bn this year and grow to US$4bn by 2024.

AstraZeneca shares rose 1% to 6,858p on Monday morning.

-- Adds analyst comment --

Quick facts: AstraZeneca

Price: 8580 GBX

LSE:AZN
Market: LSE
Market Cap: £112.59 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

4D Pharma PLC about to start dosing patients in its Phase II trial for COVID-19

4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs. ''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our...

1 day, 2 hours ago

2 min read